Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) stock analysis

KNSA · Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

Latest recorded price: USD 94.23

Model-estimated fair value: USD 18.29. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic

At $94.23, KNSA trades 415.3% above the model's base-case value of $18.29. Using FCFF DCF, the model estimates $14.49 in the conservative case and $26.85 in the optimistic case, with a valuation confidence score of 55/100. About 84% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 45.5%, free cash flow margin 20.1%. The model flags 1 risk signal for this company.

Similar companies in Healthcare